Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, variant U1 small nuclear 19 (RNVU1-19), also referred to as vU1.19 and by several related names, is a member of the variant U1 small nuclear RNAs. U1 snRNA is a noncoding RNA essential for the function of the spliceosome, the molecular complex responsible for the removal of introns from pre-mRNAs. The U1 snRNA gene family includes numerous variant genes (vU1s) such as vU1.19, which are expressed at much lower levels than the canonical U1 snRNA. These variants are transcribed, capped, and incorporated into small nuclear ribonucleoprotein complexes (snRNPs), and vU1.19 can be found in spliceosomes. Unlike canonical U1, vU1.19 has not demonstrated the ability to support pre-mRNA splicing in reconstituted assays. vU1 family members may have cell type-specific expression patterns and have been implicated in stem cell biology and possible disease modulation through altered ratios with canonical U1 snRNA. However, there1 is currently no evidence that vU1.19 is a stand-alone therapeutic target, nor are there any known drugs or biomarkers specifically interacting with or detecting this variant[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, variant U1 small nuclear 19 (RNVU1-19).